GleamWall
中文EN

HIND Vyome Holdings, Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1427570 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-55.6%
TTM net income YoY59.8%
TTM EPS YoY100.2%
Revenue 3-yr CAGR-75.0%
Net income 3-yr CAGR—

Margins

Gross margin50.4%
Operating margin-2,853.6%
Net margin-2,455.6%
FCF margin—
EBITDA margin-2,846.7%

Returns

ROE-95.7%
ROA-48.0%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets24.0%
Debt / equity0.00x
Current ratio3.68x
Interest coverage-229.34x

Cash quality & payout

Operating cash flow / net income1.18x
Accruals ratio8.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$319,714$256,944
Cost of revenue$100,943$61,974
Gross profit$218,771$194,970
R&D expense$588,258$285,391
SG&A expense$2.37M$898,572
Operating income-$10.45M-$1.01M
Interest expense$146,641$206,004
Pretax income—-$7.09M
Income tax—$39,000
Net income-$10.26M-$1.45M
EBITDA-$10.44M-$988,993
EPS (basic)-4.86-6,001.39
EPS (diluted)-4.86-6,001.39
Weighted avg. shares (diluted)2.16M241
Balance sheet
Cash & equivalents$4.98M$101,904
Receivables$325$2,294
Inventory—$2.46M
Current assets$5.44M$302,046
PP&E, net$46,393$59,179
Intangibles$314,191$314,191
Total assets$6.50M$1.38M
Current liabilities$2.74M$5.74M
Short-term debt—$811,000
Total liabilities$2.74M$5.77M
Shareholders' equity$2.44M-$4.39M
Shares outstanding5.92M0
Cash flow statement
Operating cash flow-$3.75M-$614,136
Investing cash flow—$315
Financing cash flow$8.65M$697,951
Depreciation & amortization$11,985$17,347
Stock-based compensation$577,128$184,000

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.